Literature DB >> 2416122

Transplantation of major ABO-incompatible bone marrow depleted of red cells by hydroxyethyl starch.

P I Warkentin, J M Hilden, J H Kersey, N K Ramsay, J McCullough.   

Abstract

23 bone marrow transplant recipients whose donors where major ABO-incompatible received marrow depleted of red cells prior to infusion utilizing gravity sedimentation in hydroxyethyl starch. The in vitro red cell-depletion procedure effectively removed 97.8% (mean) of the red cells from the harvested marrows and preserved 86.8% of the nucleated cells and 98.2% of the CFU-C activity in 25.4% of the original volume. All recipients had a significant quantity of isohemagglutinins of both IgM and IgG classes demonstrable in their serum at the time of the marrow infusion. Patients were premedicated and well-hydrated prior to the infusion and tolerated the infusion well. These patients demonstrated bone marrow engraftment at the same rate as did those patients whose marrow donors were either ABO-identical or minor ABO-incompatible. There was no difference in the incidence of or time to development of graft versus host disease, the incidence of graft rejection, or patient survival among the groups. Recipients of red cell-depleted major ABO-incompatible bone marrow transplants demonstrated production of donor-type red cells somewhat later and required slightly more red cell transfusion support that did the other groups of recipients. This red cell-depletion technique is safe and effective in the management of major ABO-incompatible bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416122     DOI: 10.1111/j.1423-0410.1985.tb00152.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

Review 1.  The processing of stem cell concentrates from the bone marrow in ABO-incompatible transplants: how and when.

Authors:  Nicola Daniele; Maria Cristina Scerpa; Cecilia Rossi; Alessandro Lanti; Gaspare Adorno; Giancarlo Isacchi; Francesco Zinno
Journal:  Blood Transfus       Date:  2013-11-21       Impact factor: 3.443

2.  Fully automated, clinical-grade bone marrow processing: a single-centre experience.

Authors:  Benedetta Mazzanti; Serena Urbani; Simone Dal Pozzo; Paola Bufano; Lara Ballerini; Alessia Gelli; Irene Sodi; Irene Donnini; Massimo Di Gioia; Stefano Guidi; Julien Camisani; Riccardo Saccardi
Journal:  Blood Transfus       Date:  2016-09-27       Impact factor: 3.443

3.  Intra-operative preparation of autologous bone marrow-derived CD34-enriched cellular products for cardiac therapy.

Authors:  Albert D Donnenberg; Vera S Donnenberg; Deborah L Griffin; Linda R Moore; Ferda Tekinturhan; Robert L Kormos
Journal:  Cytotherapy       Date:  2010-11-09       Impact factor: 5.414

4.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

5.  Acquired immune haemolysis by anti A 1 antibody following bone marrow transplantation.

Authors:  R J Haas; P Rieber; M Helmig; E Strobel; B H Belohradsky; M U Heim
Journal:  Blut       Date:  1986-11

6.  Infusion hemolysis after pediatric major ABO-mismatched bone marrow transplant: Comparison of two red blood cell depletion techniques.

Authors:  Robert Sheppard Nickel; Muna Qayed; Diana Worthington-White; Sean R Stowell; Kuang-Yueh Chiang
Journal:  Pediatr Blood Cancer       Date:  2017-11-08       Impact factor: 3.838

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.